我們已在上線！ 進一步了解
KOD圖示

Kodiak Sciences
KOD

85.75 USD
-2.37
2.69%
收盤時 已更新 10月16日 下午4:00 EDT
盤前交易
盤後交易
85.00
-0.75
0.87%
1天
-2.69%
5天
-14.32%
1個月
161.67%
3個月
107.88%
6個月
112.2%
今年迄今
229.55%
1年
474.73%
5年
-23.28%
10年
744%
 

關於： Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

員工： 124

醫療保健 生物科技

新聞

正面
中性
負面
市場情緒 3個月
正面 40%
中性 50%
負面 10%
中性
Schaeffers Research
4 天前
11 Stocks Most Likely to See a Short Squeeze Rally
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
11 Stocks Most Likely to See a Short Squeeze Rally
中性
PRNewsWire
10 天前
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration scheduled for AAO 2026. Additional presentations include Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy and Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation (MESI).
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
負面
Benzinga
12 天前
Top 3 Health Care Stocks That May Collapse In Q4
As of Oct. 5, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Top 3 Health Care Stocks That May Collapse In Q4
中性
MarketBeat
14 天前
Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study
Kodiak Sciences NASDAQ: KOD reported that its Phase III DAYBREAK study met primary endpoints for two investigational treatments in treatment-naïve patients with wet age-related macular degeneration, or wet AMD, with both therapies demonstrating statistical equivalence to aflibercept on visual-acuity outcomes.
Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study
負面
24/7 Wall Street
17 天前
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
正面
Zacks Investment Research
17 天前
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
正面
The Motley Fool
18 天前
Why Kodiak Sciences Skyrocketed Today
Zenkuda and KSI-501 achieved their primary goals in a Phase 3 study. The global market for retinal drugs could exceed $32 billion by the end of the decade.
Why Kodiak Sciences Skyrocketed Today
中性
Seeking Alpha
18 天前
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
正面
Proactive Investors
18 天前
Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
Kodiak Sciences Inc (NASDAQ:KOD) surged after Zenkuda and tabirafusp-ted met their primary endpoints in the phase III DAYBREAK trial for wet age-related macular degeneration. Shares gained over 162% by midday Monday following the announcement.
Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
正面
Benzinga
19 天前
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
Kodiak Sciences Inc. (NASDAQ:KOD) on Monday released data from the Phase 3 DAYBREAK trial for patients suffering from wet age-related macular degeneration (wAMD).
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
查看新聞排名
價格圖表採用Lightweight Charts™實作